URO TODAY: Benign prostatic hyperplasia patients in whom prostate cancer is suspected and who have urination problems, with a previously negative biopsy result, can undergo transurethral resection of the prostate, which treats bladder outlet obstruction and gives early diagnosis of prostate cancer. READ MORE>
Archive for the ‘Enlarged prostate’ Category
TURP is useful for diagnosing early stage prostate cancer
Posted in Diagnosis, Enlarged prostate, PROSTATE CANCER, PROSTATE RESEARCH, Trans-urethral re-section, Urination, tagged benign prostatic hyperplasia, Biopsy, bladder outlet obstruction, cancer research, catheter, early diagnosis of prostate cancer, Enlarged prostate, Incontinence, lower urinary tract symptoms, previously negative biopsy, prostablog, prostate, prostate blog, PROSTATE CANCER, quality of life, transurethral resection, Urination, urination problems, URO TODAY on June 20, 2010| Leave a Comment »
Combo drug for prostatic hyperplasia in men with enlarged prostate
Posted in Enlarged prostate, PROSTATE CANCER, tagged cancer research, catheter, Enlarged prostate, GlaxoSmithKline, Jalyn, PHARMA TIMES, prostablog, prostate, prostate blog, prostatic hyperplasia on June 17, 2010| Leave a Comment »
PHARMA TIMES: US regulators have approved GlaxoSmithKline’s combination drug, Jalyn, to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate. READ MORE>
New drug for treating benign prostatic hyperplasia enters phase 2 clinical trial in US
Posted in Enlarged prostate, PROSTATE CANCER, Treatment news, tagged Aptocine(TM) (talaporfin sodium), benign prostatic hyperplasia, BIO-MEDICINE, Enlarged prostate, innovative targeted drug treatment, Light Sciences Oncology Inc., Phase 2 clinical trial, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate on August 20, 2009| Leave a Comment »
BIO-MEDICINE: The first patients have entered a Phase 2 clinical trial of a innovative targeted drug treatment, Aptocine(TM) (talaporfin sodium), for benign prostatic hyperplasia (enlarged prostate). READ MORE>
PROSTATE RESEARCH: Surgery for benign enlarged prostate doesn’t eliminate cancer risk
Posted in Enlarged prostate, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged benign enlarged prostate, benign prostatic hyperplasia, cancer research, Enlarged prostate, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, residual tissue, URO TODAY on June 20, 2009| Leave a Comment »
JUNE 20: URO TODAY: Men undergoing surgical interventions for benign enlarged prostate are still at risk for subsequent development of prostate cancer due to residual tissue. READ MORE>
PROSTATE EXAMS: Doctor writes about wierd way he was taught to do digital exams
Posted in Checkups, Diagnosis, Digital exams, Enlarged prostate, PROSTATE CANCER, tagged digital diagnosis, digital examination, Enlarged prostate, medical checkups, prostablog, prostate, prostate blog, PROSTATE CANCER, TALES FROM SERENITY NOW HOSPITAL on May 26, 2009| Leave a Comment »
MAY 26: TALES FROM SERENITY NOW HOSPITAL: How some (semi-literate) US doctors learn to perform digital examinations on patients – a bizarre tale: “The patient (sic) recieved 100 dollars per five rectals or 20 bucks each finger. Many of these patients smelled of alcohol, had no teeth, had mental illnesses, and were addicted to IV drugs…” READ MORE>
PROSTATE RESEARCH: Drug used for enlarged prostate also reduces cancer risk
Posted in Enlarged prostate, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged benign prostatic hyperplasia, cancer research, Dutasteride (Avodart), Enlarged prostate, prostablog, prostate, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate on April 29, 2009| Leave a Comment »
BIO-MEDICINE: Dutasteride (Avodart), a commonly prescribed drug to treat benign prostatic hyperplasia, has been shown to lower the risk of prostate cancer by 23 percent in men with an increased risk of the disease, according to results of an international clinical trial presented yesterday at the American Urological Association annual meeting in Chicago. READ MORE>